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RESEARCH PAPERS 
The small heat shock protein Hsp31 cooperates with 
Hsp104 to modulate Sup35 prion aggregation 
Kiran Aslam, Chai-jui Tsai, and Tony R. Hazbun 
Department of Medicinal Chemistry and Molecular Pharmacology and the Purdue 
University Center for Cancer Research, Purdue University, West Lafayette, IN, USA 
ABSTRACT. The yeast homolog of DJ-1, Hsp31, is a multifunctional protein that is involved in several 
cellular pathways including detoxification of the toxic metabolite methylglyoxal and as a protein 
deglycase. Prior studies ascribed Hsp31 as a molecular chaperone that can inhibit a-Syn aggregation in 
vitro and alleviate its toxicity in vivo. It was also shown that Hsp31 inhibits Sup35 aggregate formation in 
yeast, however, it is unknown if Hsp31 can modulate [PSIC] phenotype and Sup35 prionogenesis. Other 
small heat shock proteins, Hsp26 and Hsp42 are known to be a part of a synergistic proteostasis network 
that inhibits Sup35 prion formation and promotes its disaggregation. Here, we establish that Hsp31 
inhibits Sup35 [PSIC] prion formation in collaboration with a well-known disaggregase, Hsp104. Hsp31 
transiently prevents prion induction but does not suppress induction upon prolonged expression of Sup35 
indicating that Hsp31 can be overcome by larger aggregates. In addition, elevated levels of Hsp31 do not 
cure [PSIC] strains indicating that Hsp31 cannot intervene in a pre-existing prion oligomerization cycle. 
However, Hsp31 can modulate prion status in cooperation with Hsp104 because it inhibits Sup35 
aggregate formation and potentiates [PSIC] prion curing upon overexpression of Hsp104. The absence of 
Hsp31 reduces [PSIC] prion curing by Hsp104 without influencing its ability to rescue cellular 
thermotolerance. Hsp31 did not synergize with Hsp42 to modulate the [PSIC] phenotype suggesting that 
both proteins act on similar stages of the prion cycle. We also showed that Hsp31 physically interacts 
with Hsp104 and together they prevent Sup35 prion toxicity to greater extent than if they were expressed 
individually. These results elucidate a mechanism for Hsp31 on prion modulation that suggest it acts at a 
distinct step early in the Sup35 aggregation process that is different from Hsp104. This is the first 
demonstration of the modulation of [PSIC] status by the chaperone action of Hsp31. The delineation of 
Hsp31’s role in the chaperone cycle has implications for understanding the role of the DJ-1 superfamily 
in controlling misfolded proteins in neurodegenerative disease and cancer. 
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INTRODUCTION 
Amyloids are highly ordered cross b-sheet 
protein polymers that are associated with a 
broad range of neurodegenerative diseases 
including Parkinson, Alzheimer, Huntington 
and Prion diseases.1,2 Growth of amyloids 
occurs by the nucleated polymerization of solu-
ble proteins of  a particular sequence.3,4 Many 
proteins can polymerize to form amyloid when 
provided an appropriate environment in vitro, 
indicating this as inherent characteristic of pol-
ypeptides. Indeed, many recent studies have 
shown the existence of beneficial amyloids that 
are  important for survival of a host organism.5
Furthermore, the highly rigid structure of self-
propagating amyloids provides a possible tool 
in  designing a unique nanomaterial.6 Therefore, 
it is important to study the process of amyloid 
formation as well as its modulation. 
Budding yeast Saccharomyces cerevisiae, 
provides a useful model to understand the for-
mation, modulation and disaggregation of amy-
 loids including prions.7 One of the most 
extensively studied yeast prions is formed from 
the translation termination factor Sup35, which 
has the normal function of releasing polypep-
tide chains from the ribosome upon encounter-
ing a stop codon. The prion form of Sup35 
involves a self-perpetuating conformational 
change that results in stop codon suppression 
and translational read-through.8 This termina-
tion defect can be visualized easily in vivo by 
nonsense suppression of a designed premature 
stop codon in a gene that affects colony color, 
thus providing a convenient phenotypic assay 
to monitor [PSIC] prion.8 
The propagation of [PSIC] prion in yeast is rig-
orously controlled by molecular chaperone 
machinery including, Hsp104, Hsp70, Hsp40 and 
their co-chaperones.9-12 Hsp104 is a member of 
AAAC ATPase superfamily and its expression is 
induced under stress to facilitate refolding and dis-
sociation of protein aggregates. 13,14 A moderate 
level of Hsp104 is required for [PSIC] prion prop-
agation as overproduction or deletion of Hsp104 
15,16cures the [PSIC] prion in yeast. Since, 
Hsp104 disaggregates the misfolded protein after 
heat shock, it is postulated that Hsp104 generates 
“propagons” by fragmenting the prion polymers 
that are available for further polymerization and 
therefore maintain the prion propagation.7 
Another model proposes that elevated levels of 
Hsp104 cure [PSIC] prion by dissolution of the 
prion seeds, the evidence for this model came 
from the observation of the diffuse expression of 
Sup35 tagged with GFP when Hsp104 was over-
expressed in [PSIC] cells,17 and a large fraction of 
soluble Sup35 was observed in the cell lysate of 
[PSIC] with excess of Hsp104 expression.18 
Recent studies also suggests that dissolution of 
prion seed might be due to trimming activity of 
Hsp104 in which Sup35 dissociates from the end 
of the prion seed thus reduces its size without gen-
erating new seeds.19,20 Trimming activity of 
Hsp104 is still present even when severing activ-
ity is inhibited by treatment of guanidine.20 
Hsp104 collaborates with Hsp70 and Hsp40 fami-
lies in dissolution of heat-damaged proteins as 
well as prion propagation.21-26 Interestingly, dif-
ferent Hsp70 homologues have opposing effects 
on [PSIC] in which the Ssa proteins antagonize 
while the Ssb proteins potentiate [PSIC] curing by  
elevated levels of Hsp104.10,27,28 Deletion of co-
chaperones of Hsp70/90 such as Sti1, Cpr7 and 
Sis1, also inhibit [PSIC] curing by Hsp104 
overexpression.10,25,29 
In addition to Hsp104 and its assistant chap-
erones, small heat shock proteins such as 
Hsp31, Hsp26 and Hsp42 also play a role in 
disaggregation of misfolded proteins in 
30-36yeast. These proteins are highly expressed 
under moderate stress and during late growth 
phase for transition to stationary phase.35,37 
Hsp42 and Hsp26 work synergistically to 
inhibit prion formation and potentiate dissolu-
tion of Sup35 prion aggregates by distinct 
mechanisms.30 Furthermore, Hsp26 or Hsp42 
collaborate with Hsp70 and or Hsp104 to 
reduce the SDS-resistant polyglutamine aggre-
gation.31,38 Hsp31 is an ortholog of DJ-1, which 
has been well established to have a role in 
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neurodegenerative disease and more recently in 
39,40cancer. Hsp31 inhibits the formation of 
a-Syn aggregates in vitro and toxicity in 
vivo.41,42 It was also demonstrated that Hsp31 
inhibits Sup35 aggregation formation in yeast41 
however, it is unknown whether Hsp31 inter-
feres with [PSIC] prion induction and propaga-
tion and if like other small heat shock proteins 
it can coordinate with Hsp104. 
In the present study, we aimed to explore the 
role of Hsp31 in prion propagation and induc-
tion using [PSIC] prion model. First, we inves-
tigated the ability of Hsp31 to inhibit Sup35 
prion aggregation and induction by overexpres-
sion of the prion-forming domain (PrD) in 
[psi¡] strain. In this study we have delineated 
the collaboration between Hsp31 and Hsp104 
on [PSIC] prion curing and prion associated 
toxicity. These results are the first evidence that 
Hsp31 acts as a chaperone protein that coordi-
nates with Hsp104 to rescue cells from prion 
toxicity. 
RESULTS 
Hsp31 Antagonizes Sup35 Aggregation 
Formation in [psi¡PINC] strain 
background 
We previously reported that Hsp31 has 
chaperone activity against Sup35 aggregates 
when tested in the wild-type (WT) W303 yeast 
strain. In this study, we validated the ability of 
Hsp31 to inhibit Sup35 fibril formation in the 
[psi¡ PINC] strain background. [PINC], an 
epigenetic element, is required to induce 
[PSIC] formation spontaneously or by overex-
pression of Sup35 or its PrD.43 The presence 
of [PINC] is necessary at early stages of prion 
formation but is not needed for maintenance 
and propagation of [PSIC].7 We overexpressed 
Hsp31-DsRed under the GPD promoter con-
comitantly with PrD-Sup35-EYFP under GAL 
expression in a [psi¡ PINC] 74D-694 strain. 
We have previously shown the DsRed-tagged 
Hsp31 is nearly functionally equivalent to an 
untagged protein because it can complement a 
hsp31D strain.41 When examined by confocal 
microscopy, PrD-Sup35 fluorescent foci were 
greatly reduced in cells co-expressing 
pAG415-GPD-HSP31-DsRed and pAG424-
GAL-PrD- Sup35-EYFP as compared to vector 
control (Fig. 1A-B). We further confirmed 
reduced foci formation by measuring fluores-
cence intensity using flow cytometry and 
obtained similar results as fluorescence 
microscopy (Fig. 1C). We have previously 
observed and established that Sup35 aggre-
gates are associated with increased fluores-
cence and can be quantified using flow 
cytometry.41 Finally, we performed semi-dena-
turing detergent agarose electrophoresis (SDD-
AGE) to determine the level of SDS-resistant 
aggregate forms. Consistent with the previous 
results, elevated Hsp31 greatly reduced the 
level of Sup35 aggregates as measured by 
SDD-AGE but did not greatly reduce the 
FIGURE 1. Hsp31 overexpression decreases the level of PrD-Sup35 aggregates. (A) GAL-driven 
PrD-Sup35-EYFP was overexpressed for 24 h at 30C in  [psi¡ PINC] cells with or without overexpres-
sion of DsRed tagged Hsp31. PrD-Sup35-EYFP aggregates appeared as ribbon-like vacuolar periph-
eral rings. Hsp31 remains cytoplasmically diffuse in these cells. Elevated levels of Hsp31 decreased 
the presence of Sup35 aggregates in individual cells. (B) Quantitation of the number of cells with one 
or more Sup35-EYFP foci. The average of at least 3 independent experiments was plotted; error bars 
represent mean §SEM. (*** unpaired Student’s t-test; p 0.001). (C) Quantitation of the level of 
Sup35-EYFP fuorescence aggregates using fow cytometry. Aggregates are associated with higher 
fuorescence. Elevated levels of Hsp31 lowered the median fuorescence intensity (FI – arbitrary units) 
of Sup35-EYFP compared to vector control. Values represent mean §SEM of 3 independent biological 
replicates (* unpaired Student’s t-test; p 0.01). (D) Cellular lysate of cells describe in A and B was 
analyzed by semi-denaturing agarose electrophoresis and SDS-PAGE. Overexpression of Hsp31 sup-
presses the level of SDS-resistant Sup35 aggregates as detected with anti-GFP antibody. Lower panel 
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overall steady-state level of Sup35 in SDS- ence of the [PINC] genetic element. It should be 
PAGE (Fig. 1D). These results show that Hsp31 noted that additional lower molecular weight 
can reduce de novo [PSIC] aggregate formation, prion forms, that might not be detected by 
as can be detected by SDD-AGE, in the pres- SDD-AGE may persist and still be infectious. 
 
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Hsp31 Transiently Inhibits Sup35 Prion 
Induction in vivo 
The ability of Hsp31 to inhibit Sup35 aggre-
gation in the [psi¡ PINC] background led us to 
investigate its ability to inhibit [PSIC] induc-
tion. Spontaneous de novo [PSIC] induction 
frequency is extremely low unless Sup35 or its 
PrD is overexpressed.8,44 This system is widely 
used to investigate the process of prion induc-
tion in yeast. To determine whether Hsp31 can 
inhibit prion induction we used a [psi¡ PINC] 
strain that forms red color colonies on 1/4 YPD 
plates with limited adenine. This strain forms 
white colonies in the presence of [PSIC] 
because soluble Sup35 is depleted by aggregate 
formation resulting in suppression of a prema-
ture stop codon and restoration of adenine pro-
totrophy. We observed that overexpression of 
Hsp31 antagonized [PSIC] prion induction trig-
gered by overexpression of Sup35 PrD for 6 h 
(Fig. 2A-B). However, when Sup35 PrD was 
expressed for 12 or 24 h, the [PSIC] prion 
induction level between vector control and 
Hsp31 was statistically similar (Fig. 2C). In 
addition, we have previously shown that Hsp31 
overexpression does not significantly alter 
Hsp104 expression levels.41 These findings 
suggested that Hsp31 antagonizes prion induc-
tion transiently but can be overcome by excess 
production of PrD or cannot intervene when 
cells have established a full and more mature 
prion cycle. In addition, the transient and non-
permanent effect on [PSIC] by overexpression 
of Hsp31 suggests that the [PINC] prion is not 
cured. These results are consistent with our 
previous proposal that Hsp31 intervenes early 
in the protein misfolding processes.41,45 
[PSIC] Prion State is not Affected by 
Hsp31 Overexpression or Deletion 
Transient overexpression of small heat shock 
proteins such as Hsp26 and Hsp42 cure the 
[PSIC] prion, converting white or pink colonies 
that reflect the strength of the [PSIC] pheno-
type, into red [psi¡] colonies on 1/4 YPD plates 
with limited adenine.30 First, we tested if over-
expression of Hsp31 can cure the [PSIC] prion. 
We used the 74D-694 [PSIC] strain which has 
a weak to moderate phenotype based on its 
pink color. Despite the fact that Hsp31 can pre-
vent de novo prion aggregate formation in vivo 
as detected by SDD-AGE (Fig. 1), overexpres-
sion of Hsp31 is not sufficient to cure the mod-
erate [PSIC] phenotype of the 74D-694 strain 
(Fig. 3A). In addition, Hsp42 was used as a 
control and was able to cure [PSIC] as previ-
ously reported.28 However, we found that 
Hsp26 overexpression using the identical plas-
mid vector from Duennwald et al.28 had 0 % 
curing of [PSIC] in this strain and under these 
experimental conditions in more than 3 biologi-
cal replicates. Our results are more consistent 
with Wickner and colleagues46 who reported 
lack of prion curing by Hsp26 for both [Ure3-
1] and [PSIC] phenotypes, which could be 
explained by differences in strain genotypes 
and experimental conditions.46 We tested dif-
ferent plasmid systems to express Hsp31 
including the GPD and GAL promoters and 
FIGURE 2. Hsp31 transiently inhibits Sup35 prion induction. (A) To induce prion formation, a GAL-
driven vector expressing PrD-Sup35-EYFP was expressed in the [psi¡ PINC] strain containing the 
ade1-14 nonsense mutation. Constitutive expression of Hsp31 was driven by the GPD promoter and 
[PSIC] formation was scored by quantifying white color colonies on 1/4 YPD plates. Top panel repre-
sents the vector controls for the expression plasmids in the bottom panel where Hsp31-DsRed, Hsp42 
and Hsp104 were overexpressed. (B) PrD-Sup35-EYFP was expressed for 6 h to transiently induce 
prion formation. Hsp31 overexpression decreased the prion induction level. Only one vector control is 
shown because other vectors had similar levels of prion induction. Error bars represent §SEM (** 
unpaired Student’s t-test; p 0.001, n D 3). (C) Time course of prion formation by pAG424-GAL-PrD-
Sup35-EYFP with varied expression times in the presence of GPD-Hsp31. Error bars represent mean 
§SEM (** unpaired Student’s t-test; p 0.001, n D 3) ns D not signifcant. All experiments in this fgure 
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none of them were able to modulate the [PSIC] PINC] hsp31D strain carrying the reporter non-
prion phenotype (data not shown). Next, we sense allele ade1-14, so that the Sup35 read-
determined if deletion of HSP31 influences the through caused by [PSIC] presence could be 
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The phenotype of the [PSIC] prion was similar 
in the hsp31D strain compared to WT with no 
change in colony color (Fig. 3B), suggesting 
that Hsp31 cannot intervene in an established 
prion cycle. 
Hsp31 Deletion Impairs [PSIC] Prion 
Curing by Hsp104 Overexpression 
A moderate level of Hsp104 is required for 
maintenance of [PSIC]; either deletion or over-
expression of Hsp104 cures the [PSIC] prion. 
Numerous chaperones such as Hsp70, Hsp40 
and Hsp90 along with its co-chaperones Sti1 
and Cpr7 are known to modulate prion curing 
by Hsp104.10,23 To determine if Hsp31 altered 
Hsp104-mediated [PSIC] prion curing, we 
transformed WT [PSIC] or  hsp31D [PSIC] cells 
with p426-GPD-Hsp104 (low level of overex-
pression), pAG425-GAL-Hsp104-DsRed 
(medium overexpression) or p2HG-Hsp104 
(high overexpression) plasmids (Fig. 3C-E). 
The varied overexpression level of Hsp104 
under these different plasmid systems was con-
firmed by western blotting (Fig. 3F). The level 
of [PSIC] prion curing was correlated to the 
level of Hsp104 expression in WT [PSIC] cells. 
The level of [PSIC] prion curing was signifi-
cantly reduced in hsp31D [PSIC] under the low-
est overexpression condition of GPD-Hsp104 
(2% compared to 7% in WT) (Fig. 3C). Under 
high overexpression of Hsp104, a 100% curing 
level was observed in the presence of HSP31 
but the hsp31D strain never achieved 100% 
curing and clearly white colonies were 
observed at 3% frequency (Fig. 3D). Intrigu-
ingly, the colonies were much whiter compared 
to the parental strain before attempting 
Hsp104-mediated curing, suggesting the colo-
nies have a stronger [PSIC] status and pheno-
type but the reason for this is unclear. We 
confirmed that these colonies do not carry 
extragenic suppressor mutations because treat-
ment with guanadine hydrochloride cured the 
[PSIC] phenotype as evidence by reversion to a 
red color (data not shown). Induction of the 
GAL-Hsp104-DsRed construct for varied time 
points from 2 h to 72 h also showed consis-
tently less efficient prion curing by the hsp31D 
strain (Fig. 3E). These results demonstrate the 
presence of Hsp31 is required for optimal prion 
curing efficiency at varied Hsp104 expression 
conditions. 
FIGURE 3. Hsp31 is required for optimal Hsp104-induced curing of the [PSIC] phenotype. (A) To 
determine the effect of Hsp31 on [PSIC] prion curing, the WT and hsp31D [PSIC] strains harboring 
the GPD-Hsp31 expression vector (pAG415-GPD-Hsp31-DsRed) or the vector (pAG415-GPD-
ccdB-DsRed) were grown for 12 h at 30C before plating on 1/4 YPD plates. (B) The WT and 
hsp31D [PSIC] strains with no vector were also grown and treated in the same way. Plates were 
grown for 2–3 d at 30C and transferred at 4C for increased color development. No difference in 
colony color was observed in these strains. (C) Low-level overexpression of Hsp104 was used to 
induce prion curing in [PSIC] hsp31D and WT strains. Cells were grown in liquid media for 12 h at 
30C before plating on 1/4 YPD plates. Signifcantly less prion curing was observed in the [PSIC] 
hsp31D strain (**unpaired Student’s t-test; p 0.001, n D 3). (D) High-level overexpression of 
Hsp104 was used to induce prion curing in [PSIC] hsp31D and WTstrains. A 100% curing level was 
observed in WT strain. In the [PSIC] hsp31D strain, 100% curing was never achieved. White color 
colonies were plotted for the WT and [PSIC] hsp31D strain (****unpaired Student’s t-test; p 
0.0001, n D 3 biological replicates). (E) Hsp104 expression under the GAL promoter for 2 to 72 h 
in WT and [PSIC] hsp31D strain. At each indicated time point, cells were plated on 1/4 YPD plates. 
Percentage of prion curing was calculated at each point for both WT and [PSIC] hsp31D strain. The 
plotted graph is one representation of 3 independent biological repeats. (unpaired Student’s t-test; 
p 0.001 at 24, 48 and 72 h; n D 3). (F) Western blot demonstrating the relative expression levels 
of Hsp104. Time points for the pGAL plasmid are represent time after switching the strain to induc-
ing galactose media. Equal amount of cells lysates were loaded in each lane and anti-histone H3 
antibody was used as a loading control. 
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Hsp31 Collaborates with Hsp104 to Cure 
[PSIC] Prion 
The decreased efficiency in Hsp104 curing 
[PSIC] in the absence of Hsp31 lead us to fur-
ther explore the relationship between these 2 
chaperones. Small heat shock proteins Hsp26 
and Hsp42 are known to collaborate with 
Hsp104 in rescuing the polyglutamine toxicity 
and solubilization of amyloid aggregates.31 We 
focused on the collaboration of Hsp104 with 
Hsp31 but it should be noted that a variety of 
other co-chaperones may also be involved but 
are beyond the scope of this study. Overall, the 
results we present herein are indicative of a 
direct effect of Hsp31 on [PSIC] as outlined in 
the discussion. We first tested the effect of 
expressing Hsp31 and Hsp104 together in cur-
ing of the [PSIC] prion. Expression of Hsp104 
(p426-GPD-Hsp104) in the [PSIC] strain 
resulted in a curing frequency of 3 % that is 
lower than that observed in Fig. 3 because the 
co-existence of 2 different constructs presum-
ably decreases plasmid copy numbers and 
affects expression levels which we have 
observed previously when expressing GAL-
Sup35-EYFP in combination with other vector 
plasmids41 and has been noted previously by 
others.47 Co-expression of Hsp31 and Hsp104 
increased the frequency of prion curing to 6 % 
compared to the respective controls (Fig. 4A). 
We also tested the collaboration between 
Hsp104 and Hsp31 in the hsp31D strain and 
detected that co-expression of Hsp104 with 
Hsp31 was able to cure the [PSIC] prion to a 
greater extent than individual chaperone 
expression (Fig. 4B). These results corroborate 
the inefficient curing in hsp31D and establish 
that Hsp31 is required for optimal Hsp104 
activity. 
Previously, it was shown that small heat 
shock protein, Hsp42, collaborates with Hsp26 
to prevent [PSIC] prionogenesis by distinct and 
synergistic mechanisms with Hsp10430 hence 
we tested the interaction between Hsp42 and 
Hsp31 on [PSIC] prion curing. Elevated levels 
of Hsp42 driven by the GPD promoter was suf-
ficient to increase curing of [PSIC] in this strain 
transformed with a single plasmid (5.4% com-
pared to 1.4%). Introduction of a second vector 
control plasmid, decreases the curing efficiency 
of the GPD-HSP42 construct to background 
levels. We also co-expressed Hsp31 and Hsp42 
in the [PSIC] strain and did not detect any 
increased curing efficiency, in contrast to 
Hsp31 co-expression with Hsp104 (Fig. 4C). 
This lack of synergy between these proteins 
implies that Hsp42 and Hsp31 act at a similar 
stage of the prion cycle. 
Effect of [PSIC] Curing in the hsp31D 
Strain is not Due to Loss of Hsp104 
Thermotolerance Function 
A possible mechanism for the decrease in 
[PSIC] prion curing by Hsp104 in the hsp31D 
background is decreased expression or activity 
of Hsp104. To measure the functional compe-
tence of Hsp104 we tested the thermotolerance 
activity of Hsp104 in exponentially growing 
cells. We induced Hsp104 expression levels in 
both strains by incubating the culture at 37C 
for 30 minute and then heat shocked at 50C. 
FIGURE 4. Expression of Hsp31 in combination with Hsp104 increases prion curing. (A) Hsp31 
and p426-GPD-Hsp104 were co-transformed in the [PSIC] strain. Vector without inserts served as 
controls. (B) Quantifcation of the experiments in panel A. Prion curing was increased from about 
2.5% to 6% when Hsp31 was co-expressed with Hsp104 compared to the control strain (*unpaired 
Student’s t-test; p 0.001, n D 3). (C) [PSIC] hsp31D strain harboring plasmids for Hsp104 and 
Hsp31. (D) Quantifcation of experiments describe in panel C. The combination of Hsp104 and 
Hsp31 increased prion curing in the [PSIC] hsp31D strain consistent with WT strain in A-B. (** One-
way ANOVA; p 0.001, n D 3). (E) Image of p426-GPD-Hsp42 transformed cells demonstrating 
curing compared to vector only. (F) Hsp31 and p426-GPD-Hsp42 were co-transformed in the 
[PSIC] strain and quantifed. The combination of Hsp42 and Hsp31 did not increase curing (ns D 
not signifcant). Data and images shown are representative of at least 3 independent biological 
experiments for all panels. 
A 8 








Hsp104 + Hsp104 + p426-GPD+ 













Hsp104 + Hsp104 + p426-GPD+ 







C .g 4 
Cl. 




Hsp42 p426-GPO Hsp42 + Hsp42 + 
Hsp31-DsRed pAG415-GPO-
ccdB 
453 Hsp31 COOPERATES WITH Hsp104 
The survival of cells after heat shock is depen- the basal thermotolerance without induction of 
dent on Hsp104 induction, and we observed Hsp104 was not affected by deletion of Hsp31 
survival in hsp31D was comparable to the iso- (Fig. 5A). In addition, we observed a slightly 
genic WT [PSIC] strain (Fig. 5A). Moreover, elevated level of Hsp104 in the hsp31D strain 
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FIGURE 5. Hsp31 interacts with Hsp104 and deletion of HSP31 does not alter Hsp104’s thermotol-
erance response. (A) HSP31 deletion does not impair Hsp104’s function in thermotolerance. Expo-
nentially growing cells of the [PSIC] hsp31D and [PSIC] strains were drawn from the culture and 
decimal serial dilutions were plated onto YPD plates and incubated for 2 d at 30C in each case. 
Both strains showed a comparable basal tolerance (top right image) and induced tolerance after 
pretreatment at 37C (bottom right image) for 30 min to a 50C heat shock treatment. Left images 
are non-treated cultures that serve as control. (B) Endogenous level of Hsp104 was determined in 
exponentially growing cultures of [PSIC] hsp31D and [PSIC] strains in YPD media using Hsp104 
specifc antibody. (C) Immunoprecipitation of Hsp31 from HSP31-9myc strain with overexpression 
of Hsp104 either under GPD or GAL promoter, using anti-myc antibody followed by immunoblotting 
with anti-Hsp104 antibody. Middle panel shows the successful pull down of Hsp31-9myc in all 
strains using anti-myc antibody. The lower panel Hsp104 was immunoprecipitated using anti-
Hsp104 antibody followed by immunoblotting with anti-myc antibody. Equal amount of cells lysates 
were loaded in each lane. 
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compared to WT, hence the expression of 
Hsp104 is not compromised (Fig. 5B). Thus, 
reduction in [PSIC] prion curing in the hsp31D 
strain is not due to general impairment of 
Hsp104 activity or expression. 
Hsp104 Physically Interacts with Hsp31 
The close collaboration between Hsp104 and 
Hsp31 prompted us to test the physical associa-
tion between them. Co-immunoprecipitation 
followed by western blot analysis in yeast 
lysates demonstrated that Hsp31 interacts with 
Hsp104. Immunoprecipitation was performed 
using HSP31-9myc genomically tagged at the 
endogenous locus and overexpressing Hsp104 
either under the GPD or the GAL promoter. 
First, Hsp31-9myc was pulled down using anti-
myc antibody conjugated to agarose beads 
from exponentially growing cell lysates. West-
ern blots confirmed the successful pull down of 
Hsp31-9myc (Fig. 5C; middle panel). The 
upper panel demonstrates the successful pull-
down of Hsp104 in both GPD-HSP104 and 
GAL-HSP104 expressing lysates but not in the 
vector control (Fig. 5C). Similar results were 
obtained with an alternative co-immunoprecipi-
tation approach in which polyclonal anti-
Hsp104 antibody and protein G dynabeads 
were used to pull down Hsp104 followed by 
western blot analysis with anti-myc antibody to 
detect Hsp31. This approach confirmed the 
interactions and also demonstrated that Hsp31 
is pulled down with strains having endogenous 
levels of Hsp104 (Fig. 5C; bottom panel vector 
control lane). These results demonstrate that 
Hsp31 physically interacts with Hsp104 using 
2 different immunoprecipitation protocols and 
the Hsp31-Hsp104 interaction is detectable 
under physiological expression levels. 
Hsp31 Together with Hsp104 Antagonizes 
Prion Dependent Toxicity of Excess 
Sup35 
Overexpression of full length Sup35 or its 
PrD exhibits toxicity in the [PSIC] strain.48,49 
The toxicity of excess Sup35 in [PSIC] or  
[PSIC] hsp31D strain was investigated. Dele-
tion of HSP31 has no effect on Sup35 toxicity 
(Fig. 6) in contrast to our previous report of 
increased toxicity when a-Syn is expressed in 
the hsp31D strain background.41 However, ele-
vated levels of Hsp31 expressed from the GPD 
promoter rescued [PSIC] cells from Sup35 tox-
icity in both WT and deleted strains. As 
expected, Hsp104 reduced the toxicity of 
Sup35 to a greater extent than Hsp31. Strik-
ingly Hsp31, together with Hsp104 strongly 
reduced the toxicity of Sup35 in the [PSIC] 
strain (Fig. 6). We also observed the rescue 
effect of sole expression of Hsp31 or Hsp104 
and when expressed together in the [PSIC] 
hsp31D strain. The level of rescue was not as 
dramatic as in the WT strains suggesting that 
the expression of endogenous Hsp31 has a role 
in reducing toxicity in conjunction with heter-
ologous expression of Hsp31 or Hsp104. The 
role of endogenous Hsp31 is not clear but could 
be a direct effect of chaperone activity or 
because autophagy can be impaired in hsp31D 
strains37 which may lead to increased proteo-
toxicity of Sup35. 
Hsp31 and Hsp104 Modulate Sup35 
Aggregation in [PSIC] Cells 
Collaboration of Hsp31 with Hsp104 to 
reduce Sup35 induced prion toxicity prompted 
us to investigate whether this activity correlates 
with protein disaggregation activity of Hsp104. 
To assess the state of Sup35 in [PSIC] cells har-
boring Hsp31 and Hsp104 expression plasmids 
(pAG415-GPD-HSP31-DsRed and p426-GPD-
Hsp104 plasmids), we performed sedimenta-
tion analysis to determine the ratio of Sup35 in 
the soluble versus aggregate forms. The indi-
vidual overexpression of Hsp104 or Hsp31 
resulted in a very strong signal in the insoluble 
pellet fraction. However, the combination of 
Hsp104 and Hsp31 markedly reduced Sup35 
aggregation found in the pellet fraction and 
increased the amount of Sup35 found in the sol-
uble fraction (Fig. 7A). Soluble Sup35 was 
very susceptible to proteolysis during process-
ing of the samples as evident by the lower 
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FIGURE 6. Hsp31 and Hsp104 reduce Sup35 prion toxicity. Hsp31, Hsp104 or the indicated combi-
nation of both along with GAL-PrD-Sup35-EYFP or full length Sup35 were overexpressed in [PSIC] 
and [PSIC] hsp31D strains. Decimal serial dilutions were plated onto selection plates with 2% glu-
cose that serve as control or 2% galactose to induce the expression. Plates were incubated at 
30C for 3 d before producing the images. Hsp31 or Hsp104 rescued toxicity of GAL-PrD-Sup35-
EYFP or full length Sup35 in these strains. Combination of Hsp31 and Hsp104 greatly reduce the 
toxicity compared to when they are individually expressed. 
18,50with earlier reports. These results demon-
strate that sole overexpression of Hsp31 does 
not appear to intervene in the established prion 
cycle present in a [PSIC] strain but can inhibit 
aggregate formation and prionogenesis in a 
[psi-] strain (Fig. 1). However, the results also 
show that Hsp31 can cooperate with Hsp104 to 
reduce Sup35 toxicity and simultaneously 
increase Sup35 solubility. 
DISCUSSION 
Previous studies have demonstrated Hsp31 is 
a multitasking protein involved in several cellu-
lar pathways ranging from functioning as a glu-
tathione independent methylglyoxalase to 
stress responder that acts as a molecular chap-
erone. In this study, we have established the 
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formation and its collaboration with Hsp104 to associated with the vacuoles. The first step in 
prevent prion aggregation and toxicity in yeast. 
In [PSIC] strains, soluble Sup35 protein is 
depleted into insoluble prion aggregates, hence, 
become less active resulting in nonsense sup-
pression.49 The stronger [PSIC] prion pheno-
type is associated with larger amounts of 
protein aggregates. Overexpression of Sup35 
PrD-EYFP in a [psi¡] strain efficiently induces 
de novo [PSIC] prion formation and resulting 
aggregates, which appear as a peripheral ring 
de novo prion induction is the formation of a 
single prion seed, also known as a 
“propagon.”51,52 These seeds sequester the sol-
uble Sup35 and grow at both ends into larger 
aggregates that appeared as rings or dots under 
microscopy. Moreover, it has been suggested 
that not all cells with fluorescent aggregates 
will transform into [PSIC] prions, rather about 
50% of the cells with fluorescent foci will die 
and some of the aggregate-containing cells 
FIGURE 7. Hsp31 acts early in the prionogenesis process. (A) Hsp31 overexpression together with 
Hsp104 decreases the aggregation of Sup35 formed by overexpression of GAL-PrD-Sup35-EYFP. 
Crude lysates of cells expressing Hsp31 (pAG415-GPD-HSP31-DsRed plasmid), Hsp104 (p426-
GPD-Hsp104 plasmid) or both together were subjected to sedimentation analysis. Lysates were 
ultracentrifuged into P (pellet) and S (soluble) fractions and analyzed by immunoblotting using 
GFP-specifc antibody. (B) Model depicting the intervention of Hsp31 during the prionogenesis pro-
cess but lack of involvement in an established chaperone cycle. Hsp31 and Hsp104 physically inter-
act but it remains to be determined if this interaction is involved in a handoff of substrates. 
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 may not possess amyloids.53 Overexpression of 
Hsp31 in a [psi¡] strain inhibits Sup35 aggre-
gate formation and this was confirmed by flow 
cytometry and SDD-AGE. These results vali-
date the previous observation that Hsp31 
 reduces Sup35 aggregates in the W303 strain.41
In addition, the inhibition of Sup35 aggregation 
by Hsp31 could result in the inhibition of prion 
formation, because the [PINC] element 
required for prion induction is present in this 
strain. It should be noted that our experiments 
did not assess the status of [PINC] and hence it 
is possible Hsp31 expression may affect 
[PINC] in addition to [PSIC]. In addition, fur-
ther testing of Hsp31 with weaker [PSIC] var-
iants could result in more robust or sustained 
curing and warrant further investigation. It 
should be noted that the 74D-694 strain [PSIC] 
used in this study had a strong enough pheno-
type to resist curing by Hsp26 but was moder-
ate at best because the strain color was pink 
rather than white. 
We observed that overexpression of Hsp31 
results in a significant reduction in prion induc-
tion from Sup35-PrD overexpression. How-
ever, reduced prion induction only takes place 
efficiently when Sup35-PrD was overexpressed 
for a transient period of time and upon longer 
expression of Sup35-PrD, Hsp31 was unable to 
reduce prion formation. Importantly, Hsp31 
alone is unable to cure the [PSIC] prion indicat-
ing that it has no disaggregase activity. We pos-
tulate that the inability of curing but the 
concomitant ability to prevent the formation of 
de novo Sup35 SDS-resistant aggregates sug-
gests that Hsp31 acts early in the process of 
prion oligomerization but once larger oligom-
ers are formed it is not further active in prevent-
ing prion propagation (Fig. 7B). 
Hsp31 may not participate in modulating an 
established prion cycle by itself but does appear 
to have a role in conjunction with Hsp104 
because in a strain lacking Hsp31, the level of 
[PSIC] curing was reduced with Hsp104 over-
expression. In addition, we showed Hsp31 
overexpression promotes the elimination of 
[PSIC] by Hsp104. In fact, another small heat 
shock protein Hsp26 was shown to potentiate 
protein disaggregation by Hsp104. Interest-
ingly, Hsp26 is only active as a disaggregase 
when it clusters together with the protein sub-
strate and not after protein aggregation.30 A 
factor in considering the mechanism of action 
is that Hsp31 and the human ortholog, DJ-1, 
have protein deglycase activity.54,55 Prion gly-
cation can occur through the action of glyoxal 
or methylglyoxal metabolites56 and the animal 
prion protein, PrPSc, has been reported to be 
modified at N terminal amino acid residues in 
clinically infected hamsters.57 Further evidence 
indicates that glycation can promote the stabil-
ity of protein aggregates by covalent crosslink-
ing58 suggesting the activity of a deglycase 
may abrogate prion propogation. Deciphering 
the contribution of the enzyme activity vs. 
chaperone function of Hsp31 would delineate 
the mechanisms of prion modulation by this 
multi-functional enzyme. We have previously 
shown that chaperone activity can be indepen-
dent of the enzyme activity because overex-
pression of an enzymatically inactive Hsp31 
mutant prevents the toxicity of a-synuclein in 
yeast.41 While there is enough evidence to pro-
pose Hsp31 acts early in the process of [PSIC] 
prion oligomerization process, future investiga-
tion of Hsp31 binding to the Sup35 monomer 
or other early oligomer and the role of deglyca-
tion in inhibiting prion induction would assist 
in elucidating the mechanism of action. 
We eliminated several possible indirect 
mechanisms for the cooperation of Hsp31 with 
Hsp104 including the possibility that disruption 
of Hsp31 might compromise Hsp104 expres-
sion and thermotolerance function (Fig. 5). 
Taking into account that deletion of Hsp31 
down regulates the mRNA level of Ssa3, a pos-
sible effect of Hsp31 deletion on [PSIC] prion 
curing by Hsp104 could be due to imbalances 
between Hsp104 and Hsp70 chaperone as these 
are required for efficient prion curing. How-
ever, this cannot be the case when Hsp31 is co-
expressed with Hsp104, as overexpression of 
Hsp31 does not alter the level of Hsp70 pro-
tein.41 An additional mechanism leading to 
Hsp104-mediated curing is that modulation of 
Hsp31 expression levels could have affect other 
co-chaperones, which are known to have a role 
in prion curing. 
We also showed that Hsp31 together with 
Hsp104 significantly reduced Sup35 prion 
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toxicity. These results indicate that Hsp31 
cooperates with Hsp104 to potentiate Sup35 
prion disaggregation and thereby prevent toxic-
ity. Intriguingly, previous studies have shown 
such cooperation between small heat shock 
proteins and ATP dependent chaperones as 
Hsp104 and Hsp70.31,38,59 We also observed a 
significant reduction of Sup35 toxicity by 
Hsp31 overexpression alone. A number of pos-
sible explanations could account for these 
results such as; Hsp31 might prevent sequestra-
tion of soluble Sup35 into already present 
larger aggregates and therefore inhibit toxicity. 
In addition, we have previously demonstrated 
that Hsp31 can reduce oxidative stress in cells41 
and this may be the reason for the rescue of 
toxicity. 
Intriguingly, we also found that Hsp31 phys-
ically interacts with Hsp104. Hsp104 is known 
to interact with Ydj1, and co-chaperones of 
Hsp90; Sti1 and Cpr7.10,26 Interestingly, Sti1 
and Cpr7 are not required for Sup35 prion prop-
agation but deletion of either of these reduced 
the Sup35 prion curing by Hsp104. Hsp31 has 
been documented to interact with the yeast 
Hsp90, Hsp82,60 based on affinity-mass spec-
trometry hence the interaction may involve a 
bridging chaperone such as Hsp90. However, 
our data is the first demonstration of Hsp31s 
interaction with Hsp104 and could mean these 
chaperones may pass substrates to each other 
and supports the hypothesis that Hsp31 affects 
[PSIC] directly. Several studies have shown 
that Hsp70 interacts with the M-domain of 
Hsp104.61 In addition, co-chaperones of Hsp90 
such as Sti1 and Cpr7 use a TPR motif to inter-
act with an acidic c-terminal tail of Hsp104.62 
Hsp31 does not have a TPR motif so further 
investigation of the possible direct interaction 
with Hsp104 could uncover a novel motif and 
mode of interaction. Although the molecular 
details of the interaction are unknown, the 
involvement of Hsp31 in the prion modulation 
process and the apparent close functional coop-
eration with Hsp104 is an important step in 
understanding the biological roles of this multi-
tasking protein. 
MATERIAL AND METHODS 
Yeast Strains and Plasmids 
[psi¡, PINC] and [PSIC] strains, derivatives 
of 74D-694 [MATa, his3, leu2, trp1, ura3; sup-
pressible marker ade1-14] were used through-
out the study for prion induction, curing and 
toxicity assays. The W303 HSP31-9myc strain 
was used for pull down assays. Details of the 
plasmid, strains and primers used in this study 
are provided in the tables (Tables 1–3). Dele-
tion of HSP31 in [PSIC] strain was obtained by 
transforming a PCR product containing the 
nourseothricin N- acetyl-transferase (NAT) 
gene flanked by HSP31 homology regions. The 
primers consisted of 20 nucleotides for ampli-
fying the NAT gene from pFA6a-NATNT2 
(Euroscarf), and 50 nucleotides immediately 
preceding the HSP31 start codon or after the 
stop codon. The amplified product was inte-
grated into [PSIC] and [psi¡, PINC] strain. Suc-
cessful integration and deletion was confirmed 
by diagnostic PCR. 
Yeast Growth Conditions 
We used isogenic [psi¡] and [PSIC] deriva-
tives of 74D-694 [MATa, his3, leu2, trp1, ura3; 
suppressible marker ade1-14. Cells were grown 
at 30C on synthetic dextrose medium (SD; 
TABLE 1. List of yeast strains used in the study. 
Strain Genotype Source/reference 
[PSIC] 74D-694 MATa ade 1–14, his3, leu2, trp1, ura3 [PSIC PINC] J-C. Rochet 
W303-1A MATa can1-100 his3-11, 15 leu2-3, 112 trp1-1 ura3-1 ade2-1 R. Rothstein 
[PSIC]-hsp31D W303-1A hsp31D::NATMX This study 
W303-HSP31-9myc W303-1A HSP31-9myc::KANMX This study 
[psi¡] 74D-694 74D-694 MATa ade 1–14, his3, leu2, trp1, ura3 [psi¡ PINC] J-C. Rochet 
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TABLE 2. List of plasmids used in the study. 
Type of Source/ 
Plasmids plasmid reference 
pAG415GPD-HSP31- Yeast, CEN This study 
dsRed 
pAG415ccdB-dsRed Yeast, CEN Alberti et al.63 
pAG424GAL-PrD- Yeast, 2 m Alberti et al.8,63 
Sup35-EYFP 
pLA1-Sup35 Yeast, CEN J. Shorter30 
p426-GPD Yeast, 2 m J. Shorter30 
p426-GPD-Hsp42 Yeast, 2 m J. Shorter30 
p426-GPD-Hsp104 Yeast, 2 m J. Shorter30 
p2HG-GPD-Hsp104 Yeast, 2 m J-C.Rochet 
p2HG-GPD Yeast, 2 m J-C.Rochet 
pAG425-GAL-ccdB- Yeast, 2 m Addgene 
DsRed 
pAG425-GAL- Yeast, 2 m This study 
Hsp104-DsRed 
0.7% yeast nitrogen base, 2% glucose) with 
appropriate amino acid dropout mixture for 
selection and maintenance of the particular 
plasmid. Synthetic complete (SC) medium con-
tains 2% raffinose in place of glucose and 2% 
galactose for induction of genes under the GAL 
promoter. 1/4 YPD solid medium used in the 
plating assays contains 0.5% yeast extract, 2% 
peptone, and 2% glucose. Cultures were always 
maintained in actively growing conditions and 
OD600 was used to measure the growth rate. 
SDD-AGE 
[psi¡] cells were co-transformed with 
pAG424-GAL-PrD-Sup35-EYFP and pAG415-
GPD-HSP31-DsRed plasmids. Cultures were 
grown in SD media overnight and induced in 
SC 2% raffinose C 2% galactose media for 
24 h. Prion aggregates were analyzed using 
SDD-AGE as described previously.41 Briefly, 
cells were harvested by centrifugation and 
spheroplasts were generated and lysed in 4 x 
SDS sample buffer at room temperature for 
15 min before loading onto a 1.8 % agarose gel 
followed by transfer to nitrocellulose mem-
brane. Immunoblots were performed using 
anti-GFP antibody (Roche; 11814460001); 
anti-DsRed antibody (Santa Cruz Biotechnol-
ogy; Sc-33353) and anti-histone H3 antibody 
(Abcam; ab1791). 
Fluorescence Microscopy and Flow-
Cytometry 
The [psi¡] strain was co-transformed with 
pAG424-GAL-PrD-Sup35-EYFP and pAG415-
GPD-HSP31-DsRed. Transformants was 
selected and re-streaked on SD (-tryptophan 
-leucine) agar plates. Cells were grown over-
night at 30C in SD (-tryptophan -leucine) 
medium and PrD-Sup35 expression was 
induced for 24 h in SC (-tryptophan -leucine) 
medium with 2% raffinose and 2% galactose. 
Cells were examined under fluorescence 
microscopy using a Nikon A1 confocal micro-
scope with a Nikon Plan apochromat 60 X (NA 
1.4) oil immersion objective to acquire fluores-
cence and DIC images and were analyzed using 
Image J. The identical cultures used in micros-
copy were also subjected to flow cytometry. 
TABLE 3. List of primers used in the study. 
Gene/description Forward Reverse 
hsp31D 
9myc tagging of HSP31 
HSP31 cloning 
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After induction cells were collected and 
washed with PBS, filtered and analyzed for 
EYFP fluorescence intensity using the Beck-
man Coulter FC500 flow cytometer with the 
FL-1 channel. A total of 10,000 events were 
acquired for each sample and data was ana-
lyzed using FlowJo software to calculate 
median fluorescence intensity. 
Sup35 Prion Curing 
Curing of [PSIC] was performed by trans-
forming the strain with plasmids; p2HG-GPD-
Hsp104, pAG425-GAL-Hsp104, pAG415-
GPD-HSP31-DsRed, p426-GPD-Hsp42 and 
their corresponding vectors. For double trans-
formation both plasmids were co-transformed 
and selected on double dropout media simulta-
neously. Transformed cells were grown in the 
SD medium at 30C for overnight growth and 
plated on 1/4 YPD plates which were incubated 
for 3 d at 30C and shifted for another day at 
4C for colony color development. To score for 
curing, colonies with red color were counted as 
[psi¡]. Cultures carrying plasmid with the GAL 
promoter were grown in SC medium before 
plating on 1/4 YPD. Plates were imaged with a 
scanner and the colonies in the images were 
analyzed and counted in a blind manner using 
the colony counting function in Image J. Sec-
tored colonies were counted as cured colonies. 
Sup35 Prion Induction 
For the induction experiment, at least 3 inde-
pendent transformants with pAG424-GAL-
PrD-Sup35-EYFP and pAG415-GPD-HSP31-
DsRed plasmid were grown at 30C in  SD  
medium overnight, centrifuges and washed 
3 times with water, and shifted to SC medium 
to induce prion formation. Aliquots were with-
drawn at 6, 12 and 48 h and diluted to a density 
of 50,000 cells per 100 ml for plating onto 1/4 
YPD plate. The plates were then incubated for 
3 d at 30C and another day at 4C for color 
development. Percentage of [PSIC] induction 
was measured as the number of white ([PSIC] 
colonies) colonies divided by the total number 
of colonies. 
Prion Toxicity Assay 
The [PSIC] strain was transformed with 
pAL1 Sup35 and plasmids expressing Hsp31, 
Hsp42 and or Hsp104 along with their corre-
sponding vector. After selection on SD plates, 
cells were grown into 5 ml of SD liquid media 
with 2 % glucose at 30C overnight. Cells were 
harvested and washed 3 times with water and a 
5-fold serial dilution was performed with a 
starting OD600 of 0.8. Diluted samples of 5 ml 
were spotted onto SD and SC plates with the 
appropriate dropout selection. Plates were incu-
bated at 30C for 3 d and imaged with a 
scanner. 
Pull Down Assay 
The HSP31-9myc tagged strain was trans-
formed with plasmids pAG425-GAL-Hsp104 or 
p426-GPD-Hsp104. Cells lysates were prepared 
in a buffer (50 mM Tris–HCl, 1 mM EDTA, 
5 mM DTT, 10% (v/v) glycerol, 0.5 M NaCl, 
at pH 7.5) with freshly added protease inhibitor 
cocktail (Roche). Anti-myc antibody-conju-
gated agarose beads were used to pull down 
Hsp31 protein by incubating the beads with the 
lysate at 4C for 1 h. After the pull down, beads 
were washed 3 times with PBS-T and bound 
protein was eluted by boiling the sample in 
SDS loading buffer before separating the pro-
teins on SDS-PAGE and western blotting using 
Hsp104 antibody (Abcam; ab69549). Immuno-
precipitation was also preformed in reverse by 
immobilizing Hsp104 antibody on protein G 
dynabeads (Life Technology) and incubating 
the total cell lysate with this complex for 1 h. 
In this case, western blotting was performed 
using anti-myc antibody (Sigma; M4439). 
Thermotolerance Assay 
WT [PSIC] and  [PSIC] hsp31D strains were 
grown in YPD medium starting from OD600 of 
0.2 until they reach exponential growth phase 
after 6 h. Equal number of cells from each 
strain were incubated at 37C to induce Hsp104 
expression and then heat shocked at 50C for  
20 min. Aliquots were placed on ice before and 
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after heat shock. A portion of cultures were heat 
shocked at 50C without Hsp104 induction at 
37C. Samples were collected and 5-fold dilu-
tions were spotted on YPD medium. 
Sedimentation Assay 
[PSIC] strains harboring Hsp31, Hsp104 and 
appropriate co-expression vector plasmids 
were grown for 12 h and centrifuged to collect 
cells. Cells were washed in water and lysed at 
4C by bead beating in lysis buffer (50 mM 
Tris HCl pH 7.5, 50 mM NaCl, 2 mM EDTA 
and 5% Glycerol plus freshly added protease 
inhibitor cocktail41). Equal volume of cold 
RIPA buffer (50 mM Tris HCl pH 7.0, 
150 mM NaCl, 1% Triton X-100, 0.5% deoxy-
cholate and 0.1 % SDS) was added to the lysate 
and the mixture was vortexed for 10 s. Lysate 
was centrifuged at 800 rpm for 2 min at 4C in  
a Eppendorf microcentrifuge. Lysate superna-
tant was subjected to ultracentrifugation at 
80,000 rpm in a TLA-120.2 rotor for 30 min 
using an Optima Max-XD Ultracentrifuge
(Beckman Coulter). Supernatant was collected 
and pellet was re-suspended in equal volume of 
lysis and RIPA buffer. Supernatant and pellet 
fractions were subjected to SDS-PAGE and
immunoblotted using GFP antibody (Roche). 
ABBREVIATIONS 
a-Syn a-Synuclein 
PD Parkinson disease 
PrD Prion-forming domain 
HSP Heat shock protein 
SC Synthetic complete 
SDD-AGE Semi-denaturing detergent aga-
rose gel electrophoresis 
SD Synthetic dextrose 
DsRed Red fluorescence protein from 
Discosoma sp 
WT Wild-type
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